ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC
Results from a phase II study of bevacizumab and erlotinib [...]
Bevacizumab plus erlotinib combination for advanced HLRCC
A recent study, published in Cancer Research and Treatment in [...]
Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer
In this video, Dr W. Marston Linehan, chief of the [...]
